ArticleClinical drug investigation2022

Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.

Qingqing Chai et al.PubMed ↗Publisher ↗

No numbers read from the abstract.